蛋白激酶C-β与糖尿病肾病研究的进展
网络出版日期: 2014-05-13
基金资助
国家自然科学基金(81270876,30771022,30971384);上海市科委优秀学科带头人基金(10XD1403400)
Advances of protein kinase C beta and diabetic nephropathy
Online published: 2014-05-13
Supported by
National Natural Science Foundation of China, 81270876,30771022,30971384;Outstanding Academic Leaders Foundation of Science and Technology Commission of Shanghai Municipality,10XD1403400
赵明明 , 刘丽梅 . 蛋白激酶C-β与糖尿病肾病研究的进展[J]. 上海交通大学学报(医学版), 2014 , 34(4) : 551 . DOI: 10.3969/j.issn.1674-8115.2014.04.030
Two isoforms of protein kinase C (PKC), i.e. PKC-βI and -βⅡ, which are encoded by the PRKCB1 gene, play important roles in the development and progression of diabetic nephropathy through the PKC signaling pathway. PKC-β inhibitor can reduce the thickness of glomerular basement membrane and microalbuminuria to protect the renal functions of diabetes patients. Polymorphisms and variants of PRKCB1 gene are relevant to increasing the risk of diabetic nephropathy and end stage renal disease by affecting its transcriptional activity, increasing insulin resistance, and promoting endothelial oxidative stress. This paper reviews the research progresses on the relationship between PKC-β and diabetic nephropathy.
Key words: protein kinase C-β; diabetic nephropathy; PRKCB1 gene
/
〈 |
|
〉 |